Title |
Advances with microRNAs in Parkinson’s disease research
|
---|---|
Published in |
Drug Design, Development and Therapy, October 2013
|
DOI | 10.2147/dddt.s48500 |
Pubmed ID | |
Authors |
Liuqing Ma, Liangming Wei, Fei Wu, Zhenhua Hu, Zhenguo Liu, Weien Yuan |
Abstract |
Parkinson's disease (PD) is the second-most common age-dependent neurodegenerative disorder and is caused by severe degeneration of dopaminergic neurons in the substantia nigra pars compacta. Unfortunately, current treatment only targets symptoms and involves dopamine replacement therapy, which does not counteract progressive degeneration. MicroRNAs (miRNAs) are a class of small RNA molecules implicated in post-transcriptional regulation of gene expression during development. Recent studies show that miRNAs are playing an important role in the pathophysiology of PD. miRNA-based therapy is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we focus on the recent advances of the use of miRNAs in the pathogenesis of PD. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 1% |
Germany | 1 | 1% |
Unknown | 74 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 12 | 16% |
Student > Ph. D. Student | 10 | 13% |
Student > Master | 10 | 13% |
Student > Postgraduate | 8 | 11% |
Researcher | 7 | 9% |
Other | 18 | 24% |
Unknown | 11 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 17 | 22% |
Medicine and Dentistry | 14 | 18% |
Biochemistry, Genetics and Molecular Biology | 13 | 17% |
Neuroscience | 7 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Other | 9 | 12% |
Unknown | 12 | 16% |